(AGENPARL) - Roma, 11 Marzo 2025 - (AGENPARL) – mar 11 marzo 2025 Lund, Sweden, 11 March 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm:
HNSA), announced today that it has completed enrolment of its 20-HMedIdeS-19
Post Authorization Efficacy and Safety (PAES) study, an open-label Phase 3
confirmatory study in Europe investigating the one-year patient and graft
survival in highly sensitized patients who have undergone HLA-incompatible
kidney transplantation following desensitization treatment with imlifidase.
Imlifidase is the Company’s first generation, first-in-class, one-time
treatment, conditionally approved in Europe as desensitization treatment in
kidney transplantation with the brand name IDEFIRIX[®].[1] Imlifidase is also
being evaluated in late-stage trials in autoimmune diseases where immunoglobulin
G (IgG) antibodies are a driver of disease, and as a pre-treatment to gene
therapy in patients with anti-AAV antibodies.
The Company anticipates data readout in the second half of 2026 followed by
submission to the European Medicines Agency to seek full authorization. The 20
-HMedIdeS-19 or PAES study is an obligation following conditional authorization
by the European Commission for IDEFIRIX[®] (imlifidase) in 2020.
Søren Tulstrup, President and CEO, Hansa Biopharma said, “The PAES study is an
important part of Hansa’s continued commitment to ensuring access to potentially
lifesaving IDEFIRIX therapy for highly sensitized kidney transplant patients, as
we believe that the evidence generated will support the submission for full
authorization in the European Union. Those considered highly sensitized and
waiting for a transplant continue to face very long wait times due to their
immunological status which poses a significant barrier to finding a compatible
organ. We believe the PAES study will underscore the strong efficacy and safety
data supporting the use of IDEFIRIX as a desensitization treatment in the pre
-transplant setting, and look forward to sharing data from the study in the
second half of 2026, following the completion of a 12-month follow-up period”.
The PAES study is a controlled, open-label post-authorization efficacy and
safety study to determine the one-year graft failure-free survival in highly
sensitized kidney transplant patients with positive crossmatch against a
deceased donor who received desensitization treatment with imlifidase followed
by an HLA-incompatible kidney transplantation. In addition to the 50 highly
sensitized adult kidney transplant patients enrolled in the study, a total of 64
patients who underwent kidney transplantation without the need for
desensitization were included in a concurrent reference cohort and as part of
the study design. The reference cohort was included in the trial to account for
the center-to-center variability in post-transplant management of patients. The
study also includes a non-comparative registry of historical data. A total of 22
sites across Europe were included.
Thomas Lorant, transplant surgeon at Uppsala University and the coordinating
investigator for the trial said, “Imlifidase is transforming transplantation
care for highly sensitized patients in Europe. Creating an IgG-free window by
inactivating the donor-specific antibodies, it makes desensitization-enabled HLA
-incompatible kidney transplantation a viable option for those considered highly
sensitized and who were previously left on transplant waiting list for extended,
often indefinite time. I am confident that imlifidase can play a key role in
allowing us to treat those kidney transplant patients with the highest need.”
EU Clinical Trials Register (https://www.clinicaltrialsregister.eu/ctr
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
Stephanie Kenney, VP Global Corporate Affairs
Notes to editors
About highly sensitized patients
Highly sensitized patients have pre-formed antibodies called donor specific
antibodies (DSAs) with a broad reactivity against human leukocyte antigens
(HLAs), which can cause tissue damage and potentially transplant rejection.[2]
The presence of DSAs means that highly sensitized patients tend to have limited
or no access to transplant, as finding a compatible donor organ can be
particularly challenging.[3,4] The complexity of their immunological profile
means that highly sensitized patients spend longer time than average on
transplant waiting lists, with evidence showing that this longer time waiting
for a suitable donor relates to an increased mortality risk.[5,6] Across the
U.S. and Europe, highly sensitized patients comprise around 10-15% of the total
of patients on transplant waiting lists.[7,8]
About IDEFIRIX[®] (imlifidase)
Imlifidase is an antibody-cleaving enzyme originating from Streptococcus
pyogenes that specifically targets and cleaves immunoglobulin G (IgG) antibodies
and inhibits IgG-mediated immune response.[1] It has a rapid onset of action,
cleaving IgG-antibodies and inhibiting their activity within hours after
administration.
Imlifidase has conditional marketing authorization in Europe and is marketed
under the trade name IDEFIRIX for the desensitization treatment of highly
sensitized adult kidney transplant patients with a positive crossmatch against
an available deceased donor. The use of IDEFIRIX should be reserved for patients
who are unlikely to be transplanted under the available kidney allocation
system, including prioritization programs for highly sensitized
patients.[1] IDEFIRIX was reviewed as part of the European Medicines Agency’s
(EMA) PRIority Medicines (PRIME) program, which supports medicines that may
offer a major therapeutic advantage over existing treatments or benefit patients
without treatment options.[1]
Imlifidase is a promising new strategy for desensitization of transplant
patients with donor-specific anti-HLA (Human Leukocyte Antigens) antibodies
(DSAs).[10] Highly sensitized patients have high levels of these preformed
antibodies that can bind to the donor organ and damage the transplant.[2] Once
they are inactivated with imlifidase, there is a window of opportunity for the
transplant to take place. By the time the body starts to synthesize new IgG, the
patient will be receiving post-transplant immunosuppressive therapy to reduce
the risk of organ rejection.
The efficacy and safety of imlifidase as a pre-transplant treatment to reduce
donor-specific IgG was studied in four phase 2 open-label, single-arm, six
-month clinical trials,[8-11] and in a long-term observational follow-up
study.[12] Hansa is collecting further clinical evidence and will submit
additional efficacy and safety data based on one post-authorization safety and
efficacy study, and a related long-term follow up study.[13,14]
Full product information can be accessed via the initial Summary of Product
Characteristics found here (https://www.ema.europa.eu/en/documents/product
-information/idefirix-epar-product-information_en.pdf).
About kidney failure
Kidney disease can progress to kidney failure or End-Stage Renal Disease (ESRD),
identified when a patient’s kidney function is less than 15%.[15] ESRD poses a
significant health burden, affecting nearly 2.5 million patients
worldwide.[15] A kidney transplant is the treatment of choice for suitable
patients with ESRD because it offers improved survival and quality of life
benefits, and is cost savings compared to long-term dialysis. There are
approximately 170,000 kidney patients in the U.S. and Europe waiting for a new
kidney.[16]
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a
mission to develop and commercialize innovative, lifesaving and life-altering
treatments for patients with rare immunological conditions. The company has a
rich and expanding research and development program based on its proprietary IgG
-cleaving enzyme technology platform, to address serious unmet medical needs in
autoimmune diseases, gene therapy and transplantation. The company’s portfolio
includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving
enzyme therapy, which has been shown to enable kidney transplantation in highly
sensitized patients and HNSA-5487, a second-generation IgG cleaving molecule
with redosing potential. Hansa Biopharma is based in Lund, Sweden, and has
operations in Europe and the U.S. The company is listed on Nasdaq Stockholm
under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on
LinkedIn (https://www.linkedin.com/company/hansa-medical-ab/).
©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and
IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All
rights reserved.
References
1. European Medicines Agency. Idefirix[®] summary of product characteristics.
Available at: https://www.ema.europa.eu/en/documents/product
-information/idefirix-epar-product-information_en.pdf.
2. Eurostam Report (A Europe-wide strategy to enhance transplantation of highly
sensitized patients on the basis of acceptable HLA mismatches.) Available
at https://cordis.europa.eu/project/id/305385/reporting.
3. Redfield RR, et al. The mode of sensitization and its influence on allograft
outcomes in highly sensitized kidney transplant recipients. Nephrol Dial
Transplant. 2016 Oct;31(10):1746-53. doi: 10.1093/ndt/gfw099.
4. Lonze BE, et al. IdeS (Imlifidase): A Novel Agent That Cleaves Human IgG and
Permits Successful Kidney Transplantation Across High-strength Donor-specific
Antibody. Ann Surg. 2018 Sep;268(3):488-496. doi: 10.1097/
5. Alelign T, Ahmed MM, Bobosha K, Tadesse Y, Howe R, Petros B. Kidney
Transplantation: The Challenge of Human Leukocyte Antigen and Its Therapeutic
6. Heidt S, et al. Highly Sensitized Patients are Well Serves by Recieving a
Compatible Organ Offer Based on Acceptable Mismatches. Front Immunol.
7. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry
of Transplant Recipients (SRTR). OPTN/SRTR 2022 Annual Data Report. U.S.
Department of Health and Human Services, Health Resources and Services
Administration; 2024. Accessed [June 2024].
8. Jordan SC, et al. Imlifidase Desensitization in Crossmatch-positive, Highly
Sensitized Kidney Transplant Recipients: Results of an International Phase 2
Trial (Highdes). Transplantation. 2021 Aug 1;105(8):1808-1817. doi:
9. Jordan SC, et al. IgG Endopeptidase in Highly Sensitized Patients Undergoing
Transplantation. N Engl J Med 2017;377:442-453. DOI: 10.1056/NEJMoa16125
10. Winstedt L, et al. Complete Removal of Extracellular IgG Antibodies in a
Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS–A Novel
11. Lorant T, et al. Safety, immunogenicity, pharmacokinetics, and efficacy of
degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney
disease patients. Am J Transplant. 2018 Nov;18(11):2752-2762. doi:
10.1111/ajt.14733.
12. Jordan SC, et al. Long-term outcomes at 5 years posttransplant in imlifidase
-desensitized kidney transplant patients. Am J Transplant. 2024 Dec 4:S1600
13. EU Clinical trial register, 20-HMedIdeS-19. Available at:
14. 20-HMedIdeS-20. Available at: https://euclinicaltrials.eu/search-for
15. NIH (2018). What is kidney failure? Available at:
https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/what
-is-kidney-failure.
16. Newsletter Transplant 2024. “International figures on donation and
transplantation 2023”. Available at: Newsletter Transplant – latest edition I
Freepub (edgm.eu) Last accessed: February 2025.
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/XUyFx3k8AKCrYbWK6tf4v5r8qRz7x9j7eq98Jh54pDAYwPVTD218RFjs4gCAiSJQKvMyAYBVu4khif7Fn62wJFkxzrsP5Ysrbz7ixYNN6Tjx3.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/XUyFx3k8AKCrYbWK6tf4v5r8qRz7x9j7eq98Jh54pDAYwPVTD218RFjs4gCAiSJQKvMyAYBVu4khif7Fn62wJFkxzrsP5Ysrbz7ixYNN6Tjx3.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
Report this content
Trending
- AGENDA CAMERA DI DOMANI, MERCOLEDÌ 18 NOVEMBRE
- L’Ambasciata d’Italia a Washington celebra la Settimana della Cucina Italiana nel Mondo con due iniziative dedicate alla promozione del patrimonio agroalimentare italiano
- DAERA News Release – MUIR ANNOUNCES PREVENTION ZONE AND HOUSING ORDER AS CO TYRONE BIRD FLU CASE CONFIRMED
- Nvidia, cresce la pressione per il ritorno di Jensen Huang: un dirigente avverte del rischio di perdere talenti fondamentali per l’intelligenza artificiale
- Ddl antisemitismo, Osservatorio Israele: “PD, AVS e M5S hanno voltato le spalle agli ebrei. Con quale coraggio celebreranno il 27 gennaio?”
- agenzia regionale 1212.26 Estorsioni imprenditori baresi, confermata condanna in appello. Il commento del presidente della Regione Decaro
- Attacco hacker a Optimizely, malware diffuso su 178 siti web: coinvolti BBC, CNN, Zoom, Salesforce e HSBC, rubate criptovalute e dati sensibili
- Camera dei deputati: Schema question time di domani
- SANITÀ, MAZZELLA (M5S): “GOVERNO TAGLIA SU SALUTE MENTRE SCHIZZA SPESA PRIVATA
- RUSSIA: BERGAMINI (FI), “BENE SANZIONI UE CONTRO LA GUERRA IBRIDA